chr2:204718611:> Detail (hg19) (CTLA4)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr2:204,718,611-204,738,688 |
| hg38 | chr2:203,853,888-203,873,965 |
HGVS
| Type | Transcript | Protein |
|---|---|---|
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
[No Data.]
DisGeNET
[No Data.]
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| Phase II randomized dose ranging study (metastatic setting). Ipilimumab elicited a dose-dependent ef... | MMMP | Detail |
| In this phase II trial (metastatic setting), anti-CTLA4 antibody tremelimumab showed an objective re... | MMMP | Detail |
| In a multicenter single-arm phase II trial of ipilimumab (monotherapy) for pretreated advanced melan... | MMMP | Detail |
| Phase III RCT. Setting: metastatic, all patients were HLA-A0201 positive. Ipilimumab, with or withou... | MMMP | Detail |
| Phase II trial. Eight (10%) of 84 response-assessable patients attained objective antitumor response... | MMMP | Detail |
| Response rate: 14% | MMMP | Detail |
| Phase III RCT of tremelimumab versus physician choice (dacarbazine or temozolomide) | MMMP | Detail |
| In this phase I-II trial, a 39% disease control rate was achieved in patients with metastatic melano... | MMMP | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- -
- Genome
- hg19
- Position
- chr2:204,718,611-204,738,688
- Variant Type
- snv
Genome browser